Timber Pharmaceuticals to Present at H.C. Wainwright BioConnect Conference
Timber Pharmaceuticals (NYSE American: TMBR) will present a corporate overview at the H.C. Wainwright BioConnect Virtual Conference, scheduled for January 10-13, 2022. The presentation will be accessible for on-demand viewing starting January 10, 2022, at 7:00 a.m. ET for conference attendees. Timber specializes in developing treatments for rare dermatologic diseases, focusing on conditions like congenital ichthyosis and facial angiofibromas. For further details, visit www.timberpharma.com.
- None.
- None.
Virtual Conference on January 10-13, 2022
BASKING RIDGE, NJ, Jan. 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that John Koconis, Chairman and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright BioConnect Virtual Conference being held on January 10-13, 2022.
The presentation will be available for on-demand viewing starting on Monday, January 10, 2022 at 7:00 a.m. ET for conference attendees. For more information on the conference, go to: www.hcwevents.com/bioconnect
About Timber Pharmaceuticals, Inc.
Timber Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases. The Company's investigational therapies have proven mechanisms-of-action backed by decades of clinical experience and well-established CMC (chemistry, manufacturing, and control) and safety profiles. The Company is initially focused on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis (CI), facial angiofibromas (FAs) in tuberous sclerosis complex (TSC), and other sclerotic skin diseases. For more information, visit www.timberpharma.com.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, intellectual property rights, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential, "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2020 as well as other documents filed by the Company from time to time thereafter with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
For more information, contact:
Timber Pharmaceuticals, Inc.
John Koconis
Chairman and Chief Executive Officer
jkoconis@timberpharma.com
Investor Relations:
Stephanie Prince
PCG Advisory
(646) 863-6341
sprince@pcgadvisory.com
Media Relations:
Adam Daley
Berry & Company Public Relations
(212) 253-8881
adaley@berrypr.com
FAQ
When will Timber Pharmaceuticals present at the H.C. Wainwright BioConnect Virtual Conference?
What is the focus of Timber Pharmaceuticals' presentation at the conference?
What is the stock symbol for Timber Pharmaceuticals?
When will the Timber Pharmaceuticals presentation be available for on-demand viewing?
What rare diseases does Timber Pharmaceuticals focus on?
